A Better Way to Look at Risk/Reward During Early Drug Development?
Jeff Kiplinger
October 16, 2015
How do you add value to a compound while maintaining cost effectiveness? The answer might depend on whether you’re part of the cautious development team, or hard-driving discovery team.
In Pharmaceutical Online’s article, “Relative Cost Models: A Better Way To Look At Risk/Reward During Early Drug Development?“, guest columnist Jeff Kiplinger considers the role chromatography plays in managing risk as chemists narrow down the number of compounds of interest.
Want to read more articles about value and risk reduction choices?
How to Calculate ROI on Discovery Scale Up Choices
When Does Asymmetric Synthesis Make More Sense Than Chiral Resolution?
Looking at Impurity Isolation Early Can Benefit Your Drug Development Process